Results 61 to 70 of about 871,553 (293)

Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies

eLife, 2017
The HIV-1 envelope (Env) glycoprotein binds to host cell receptors to mediate membrane fusion. The prefusion Env trimer is stabilized by V1V2 loops that interact at the trimer apex.
Haoqing Wang, Harry B Gristick, Louise Scharf, Anthony P West Jr, Rachel P Galimidi, Michael S Seaman, Natalia T Freund, Michel C Nussenzweig, Pamela J Bjorkman   +8 more
doaj   +1 more source

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells [PDF]

, 2008
Background: The hemagglutinin (HA) glycoprotein is the principal target of protective humoral immune responses to influenza virus infections but such antibody responses only provide efficient protection against a narrow spectrum of HA antigenic variants ...
Poon Leo L. M., Carsetti Rita, van der Meulen, J., Cinatl, J, Cox Freek, Guan, Yi, Ignace Lasters, Brink, Edward van den, van Deventer, W.B.E., Jongeneelen, M, ter Meulen Jan, Edward van den Brink, de Kruijf, C.G., de Kruif John, van Deventer, Els, Cinatl Jindrich, van Deventer, E, Peiris, M, Jaap Goudsmit, Carsetti, Rita, Throsby, Mark, Carsetti, R., Leo L M Poon, Cornelissen, L., Arjen Bakker, Kruijf, C.G., de, Throsby Mark, Lasters, I., Rita Carsetti, de Kruif, J, van den Brink, E., Poon, L.L.M., Freek Cox, Yi Guan, Goudsmit, J., Lisette Cornelissen, Els van Deventer, Cornelissen Lisette, de Kruif, John, Jongeneelen Mandy, Alard Philippe, Goudsmit Jaap, Guan Yi, Guan, Y, Alard, P., Brink, E., van den, ter Meulen, Jan, Peiris Malik, Deventer, Els van, Kruif, John de, Cinatl, J., John de Kruif, Jan ter Meulen, Cornelissen, L, Cox, F, Cox, Freek, Goudsmit, J, Cox, F., Poon, LLM, Bakker, A.B.H., Jindrich Cinatl, Lasters, Ignace, Jongeneelen, M., van Deventer Els, Mandy Jongeneelen, Poon, Leo L. M., Meulen, J., van der, Bakker, Arjen, Cinatl, Jindrich, van den Brink, E, Malik Peiris, Peiris, Malik, van den Brink Edward, Deventer, W.B.E., van, Bakker, A, van den Brink, Edward, Bakker Arjen, Mark Throsby, Throsby, M., Lasters, I, Guan, Y., Alard, Philippe, ter Meulen, J, Carsetti, R, Philippe Alard, Cornelissen, Lisette, Goudsmit, Jaap, Jongeneelen, Mandy, Peiris, M., Throsby, M, Meulen, Jan ter, Alard, P, Lasters Ignace   +92 more
core   +1 more source

Hemagglutinin sequence conservation guided stem immunogen design from influenza A H3 subtype [PDF]

, 2015
Seasonal epidemics caused by influenza A (H1 and H3 subtypes) and B viruses are a major global health threat. The traditional, trivalent influenza vaccines have limited efficacy because of rapid antigenic evolution of the circulating viruses.
Citron, Michael, Ferrara, Francesca, Temperton, Nigel J., Flynn, Jessica A, Raghavan eVaradarajan, Vamsee Aditya Mallajosyula, V., Raghavan Varadarajan, Flynn, Jessica A., Temperton, Nigel J, Xiaoping eLiang, Vamsee Aditya Mallajosyula, V. Vamsee Aditya Mallajosyula, Michael Citron, Nigel J. Temperton, Xiaoping Liang, Mallajosyula, Vamsee Aditya V, Jessica A. Flynn, Liang, Xiaoping, Varadarajan, Raghavan, Michael eCitron, Francesca eFerrara, Nigel James Temperton, Jessica A Flynn, Francesca Ferrara, Mallajosyula, Vamsee V A   +24 more
core   +1 more source

SARS-CoV-2 fusion-peptide-directed antibodies are elicited by natural infection and can mediate broad sarbecovirus neutralization

Cell Reports
Summary: Studies have demonstrated that repeated mRNA vaccination enhances the breadth of neutralization against diverse severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. However, the development of antibodies capable of neutralizing
Alex L. Roederer, Chia Jung Li, Eunice Lim, Yi Cao, Larance Ronsard, Daniel Lingwood, David H. Canaday, Stefan Gravenstein, Alejandro B. Balazs   +8 more
doaj   +1 more source

Large-scale analysis of B-cell epitopes on influenza virus hemagglutinin - implications for cross-reactivity of neutralizing antibodies

Frontiers in Immunology, 2014
Influenza viruses continue to cause substantial morbidity and mortality worldwide. Fast gene mutation on surface proteins of influenza virus result in increasing resistance to current vaccines and available antiviral drugs.
Jing eSun, Jing eSun, Ulrich eKudahl, Ulrich eKudahl, Zhiwei eCao, Christian eSimon, Christian eSimon, Ellis L Reinherz, Ellis L Reinherz, Ellis L Reinherz, Vladimir eBrusic, Vladimir eBrusic   +11 more
doaj   +1 more source

Genetic and immunological characterization of new subtype G envelope expressing HIV-1 pseudoviruses [PDF]

, 2014
Includes bibliographical references.One of the greatest challenges for the development of an effective HIV-1 vaccine is the high genetic diversity of this pathogen and the complex escape mechanisms employed by the envelope gp120 and gp41 glycoprotein ...
Essomba, Rene Ghislain
core   +1 more source

The potential of broadly neutralizing antibodies for HIV prevention. [PDF]

J Int AIDS Soc
Gelderblom HC, Corey L, Barouch DH.
europepmc   +4 more sources

Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies

Retrovirology, 2018
Anti-HIV-1 broadly neutralizing antibodies (BnAbs) exhibit an impressive capacity to protect against chimeric SIV-HIV (SHIV) challenges in macaques and potently reduce viremia in both SHIV-infected macaques and HIV-1-infected humans.
Matthew S. Parsons, Amy W. Chung, Stephen J. Kent   +2 more
doaj   +1 more source

A sweet surprise for HIV broadly neutralizing antibodies [PDF]

Nature Medicine, 2012
The production of cross-reactive neutralizing antibodies is the ultimate goal in HIV vaccine development, but no immunogen other than HIV itself has been able to elicit this type of humoral immunity. In natural HIV infections, these antibodies take several years to develop.
Langedijk, Johannes P. M., Schuitemaker, Hanneke   +1 more
openaire   +3 more sources

Recent progress in broadly neutralizing antibodies to HIV [PDF]

Nature Immunology, 2018
In this Review, we highlight some recent developments in the discovery and application of broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); i.e., antibodies able to neutralize diverse isolates of HIV. We consider the characterization of novel bnAbs, recent data on the effects of bnAbs in vivo in humans and animal models ...
Devin Sok, Dennis R. Burton
openaire   +2 more sources